Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.

× No keyword cloud information.

37 in total

1. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.

Authors: Juandong Wang; Tao Huang; Jianzhi Sun; Yuan Yu; Zhifang Liu; Wenjuan Li; Jihui Jia; Chunyan Chen
Journal: Med Oncol Date: 2014-07-15 Impact factor: 3.064

2. c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Authors: Claire M Lucas; Robert J Harris; Athina Giannoudis; Richard E Clark
Journal: Haematologica Date: 2015-02-06 Impact factor: 9.941

Review 3. Selection of therapy: rational decisions based on molecular events.

Authors: Jamshid S Khorashad; Michael W N Deininger
Journal: Hematol Oncol Clin North Am Date: 2011-10 Impact factor: 3.722

4. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

Authors: Michael W Deininger; Kenneth J Kopecky; Jerald P Radich; Suzanne Kamel-Reid; Wendy Stock; Elisabeth Paietta; Peter D Emanuel; Martin Tallman; Martha Wadleigh; Richard A Larson; Jeffrey H Lipton; Marilyn L Slovak; Frederick R Appelbaum; Brian J Druker
Journal: Br J Haematol Date: 2013-11-04 Impact factor: 6.998

Review 5. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.

Authors: Jorge Cortes; Andreas Hochhaus; Timothy Hughes; Hagop Kantarjian
Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544

6. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors: C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal: Leukemia Date: 2015-03-13 Impact factor: 11.528

7. Management of imatinib-resistant patients with chronic myeloid leukemia.

Authors: Pavan Kumar Bhamidipati; Hagop Kantarjian; Jorge Cortes; A Megan Cornelison; Elias Jabbour
Journal: Ther Adv Hematol Date: 2013-04

Review 8. Chronic myeloid leukemia: reminiscences and dreams.

Authors: Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal: Haematologica Date: 2016-05 Impact factor: 9.941

Review 9. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.

Authors: Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal: Expert Rev Anticancer Ther Date: 2013-12 Impact factor: 4.512

10. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors: Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal: Haematologica Date: 2009-08-27 Impact factor: 9.941